Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. - Wikidata - awgldk - TriplyDB

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

http://www.wikidata.org/entity/Q43445863

about

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Pharmacogenomics and cardiovascular disease Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association Clopidogrel: the data, the experience, and the controversies.Use of genetic data to guide therapy in arterial disease.Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Clinical pharmacogenetics implementation: approaches, successes, and challenges Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Antiplatelet drug interactions with proton pump inhibitors Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.Implementing genotype-guided antithrombotic therapy.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.Clinical importance of aspirin and clopidogrel resistance Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.Pharmacogenomics: the genetics of variable drug responses.Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Clinical evidence of interaction between clopidogrel and proton pump inhibitors Humanizing thrombi in mice.Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Cardiovascular pharmacogenomics Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

P2860

Q26745754-C82EEBEC-E36F-41AC-9B4C-85F134BEC22A Q26801867-501BE7E3-BB6E-4FF6-A91F-6CF668D904D1 Q26822796-9EC1C818-EBE2-4AF4-92C2-CDD06D881474 Q26997380-D2F0C0E5-800B-4AA3-AA48-BF62B4B9EF88 Q28553219-027B96B5-8A14-436F-A405-EE19C342B9A4 Q30359686-161B5975-9BA4-4FC3-8C1D-F8F7A0D53E19 Q30573045-FA825D67-89CE-47E6-B082-A35EDBED3280 Q30978916-7D60FE3C-C8B6-46D7-AADE-F9C10E3FF685 Q33561577-2618D2CA-1B6C-4F4C-8B8A-C4EC0AF39E53 Q33584173-ABB808CB-E199-4B7B-A456-E5418A276D57 Q33818356-E8432063-FBC8-4306-A58C-7FB73B914FB6 Q33825186-00D3465A-75AD-4894-B4ED-F17411F9159D Q33853179-00AF6636-742B-457C-A991-E69A39E9DFF5 Q33863833-3A7947BD-E565-4A82-8EB5-D3DE83503FA6 Q33902628-1F4539FD-90B6-432A-B8B7-B520EFFE15F6 Q33948811-3AB8B902-7C71-4BFC-B0A4-19DB53DFAEA5 Q33988457-864CE7F6-7CCB-4D12-B6BB-042FEE785C1E Q33990428-6ADB0AEA-3E9B-4A5B-A285-FD3912866D06 Q34131354-DEED226C-A9CC-4491-BBC9-52FFC653DF26 Q34150640-2EEC0AB8-03C5-4D0E-AD34-1A4675D7FD0B Q34161006-046C5190-2692-44BF-9EF2-D055FFB5633E Q34166239-6BB4ED7B-9EB8-480A-947A-771025ADC5AC Q34174915-25630579-F052-4713-90E9-2935138CB2D4 Q34352152-09508FDD-8A30-4473-A2F0-DF40CB9BE228 Q34382431-EF9E2233-488A-45EE-9DB8-4952E26BF9B8 Q34390050-9D94B4F2-0DB7-4CF3-9180-103FC4784869 Q34564576-52D9B3F8-0E18-4366-BAEB-A86D2E833769 Q34577974-B9E75FF1-F4E5-4CC9-867B-530C7E37613D Q34608705-0E428A25-B0DE-4C7E-9296-57870FD89E8C Q34624862-26E2D457-B0C1-4EDD-AD00-3DE3CC78BF34 Q34633385-1AF53AB5-1D6E-49BA-8D22-2CD1C8A50549 Q34976915-8E735387-FBAC-4747-A240-EFCF34C7C1CB Q34981428-33ABDA97-3092-42E3-80A9-6D3EE1638176 Q34990721-2CB9F9D6-2F6C-43E0-A16B-16C1D8706744 Q35015993-ED521162-2343-45FC-8B34-3A814BBF9F07 Q35033722-F478DB77-DDC9-41CA-BF22-9941F89ECA22 Q35109254-DB8027BE-C87F-48B6-B48E-E84882C82E88 Q35141772-652A257A-D937-4033-BCF7-7F4FC9A66A6E Q35447163-1817EC9B-6179-4046-B42F-558E6198D1F6 Q35603072-B68033A4-D166-4149-B8E4-99F46E921633

P2860

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

http://www.wikidata.org/entity/Q43445863

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@en

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@nl

type

label

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@en

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@nl

prefLabel

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@en

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@nl

P1433

Q43445863-2CF69A3A-EBA0-42ED-8A20-A22DC3F0151B

P1476

Q43445863-8AC9B5E7-CD16-4F77-B90B-34E2B84C89B1

P2093

Q43445863-204BFA4D-0933-4D8F-BF38-F584D5E55D42

Q43445863-30E26CFE-3538-4A70-8448-7834FDE8F1F4

Q43445863-8CBB3817-030A-4DCA-837E-BB8BD036D1CD

Q43445863-A13B1011-784F-47FA-B010-59E7B3793A2D

Q43445863-AD160582-C4E3-44CC-AFC8-97566985CB83

Q43445863-B94C5805-F08B-49F8-9F61-C8B1AB3827CE

Q43445863-BBDE992B-C260-44B4-BD35-E5D9EB0B26E0

Q43445863-C2E0D988-E332-4EBF-8DB7-2FD978F9BCE1

Q43445863-E514C766-66A1-42D0-9769-23224B8A2FC6

P304

Q43445863-9B367401-0466-4C4B-8BCC-73FD80EA7DD4

P31

Q43445863-8F9D49A9-A979-46A8-A02D-B38BB3DD4443

P356

Q43445863-A368E1AE-7792-4AB4-A42D-C29B487A8A1D

P407

Q43445863-DBE802DA-DA14-4D36-96CF-713FAD36682D

P433

Q43445863-DDBAC549-51DD-4032-B240-7B7275343598

P478

Q43445863-83733EE8-6FA2-4937-8D67-B029F2AE3B7E

P50

Q43445863-87E91D89-61D5-4DD9-A49D-D90C2B6C8E72

Q43445863-C9257C02-F744-4206-AD62-27BA966932B3

P577

Q43445863-86282654-60D9-4AD8-BBB8-EFA7FFB8D999

P5875

Q43445863-A09B3B1F-E32E-423D-9C05-9838F5B6B0F9

P698

Q43445863-29A5DFF7-3685-478D-A448-5C1135268F9E

P356

CIRCULATIONAHA.109.851949

P1433

P1476

Cytochrome P450 genetic polymo ...... ynamic, and clinical outcomes.

@en

P2093

Jessica L Mega

http://www.w3.org/2001/XMLSchema#string

John T Brandt

http://www.w3.org/2001/XMLSchema#string

Joseph R Walker

http://www.w3.org/2001/XMLSchema#string

Lei Shen

http://www.w3.org/2001/XMLSchema#string

Marc S Sabatine

http://www.w3.org/2001/XMLSchema#string

Richard D Hockett

http://www.w3.org/2001/XMLSchema#string

Sandra L Close

http://www.w3.org/2001/XMLSchema#string

Stephen D Wiviott

http://www.w3.org/2001/XMLSchema#string

William L Macias

http://www.w3.org/2001/XMLSchema#string

P304

2553-2560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.109.851949

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

Elliott M Antman

P577

2009-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24400963

http://www.w3.org/2001/XMLSchema#string

P698

19414633

http://www.w3.org/2001/XMLSchema#string